Bansisons Tea Industries is now Novyra Pharmachem Limited. The company approved a capital reduction scheme and appointed Mr. Anilkumar Amreliya as Managing Director at its 39th AGM.
Novyra Pharmachem Limited: From Tea to Pharma, with a Capital Overhaul
Novyra Pharmachem Limited, formerly Bansisons Tea Industries Ltd, has officially begun its transformation, marked by a name change and a proposed capital reduction scheme. These significant decisions were deliberated and advanced during the company's 39th Annual General Meeting (AGM) held on June 25, 2026.
What just happened
At the 39th AGM, shareholders of Bansisons Tea Industries Ltd approved the adoption of financial statements for FY 2026, re-appointed Mr. Sandeep Agarwal, and crucially, voted on a Scheme of Capital Reduction. Additionally, Mr. Anilkumar Amreliya was regularized and appointed as the new Managing Director, signifying a leadership shift. The company also confirmed a clean audit report for the fiscal year ending March 31, 2026.
Why this matters
The rebranding to Novyra Pharmachem Limited indicates a strategic pivot away from the tea business towards a new sector, likely pharmaceuticals. The proposed capital reduction is a significant corporate action that could alter the company's equity structure and financial leverage. The clean audit report provides a degree of financial transparency and reliability.
The backstory
Bansisons Tea Industries Ltd has been a player in the tea industry. The decision to rebrand and pursue a capital reduction signals a major strategic restructuring, aiming to align the company with new business objectives and potentially a new industry focus, as suggested by the name Novyra Pharmachem.
What changes now
Following the AGM, the company will proceed with the necessary regulatory approvals for the Scheme of Capital Reduction. The leadership transition, with Mr. Anilkumar Amreliya at the helm as MD, will also be implemented. Investors should anticipate further announcements regarding the execution of the capital reduction plan and the evolving business direction.
Risks to watch
Execution risk associated with the capital reduction scheme and the success of the transition into the pharmaceutical sector are key areas for investors to monitor. The company's ability to establish a strong foothold in its new chosen industry will be critical.
Peer comparison
As the company transitions into the pharmaceutical sector, its performance will be increasingly compared against peers in the Novyra Pharmachem industry, rather than traditional tea companies.
Context metrics (time-bound)
At its 39th AGM on June 25, 2026, Novyra Pharmachem Limited (formerly Bansisons Tea) approved its FY 2026 financial statements and a capital reduction scheme. The audit report for the year ending March 31, 2026, was clean.
What to track next
Investors should closely watch the regulatory filings related to the capital reduction scheme's approval and implementation, as well as any future disclosures detailing Novyra Pharmachem's strategic initiatives in its new business domain.